CNBC's Charlotte Reed will travel to Copenhagen to speak with Novo Nordisk's new CEO after a bumpy few months.

Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO ...

Viking Therapeutics is mispriced due to the successful but misunderstood clinical results of their oral GLP-1 treatment. Read ...

There’s plenty of reason to remain bullish on Novo Nordisk. Even with the challenges it has faced recently, the company ...

Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.

Drugmaker Pfizer on Friday sued obesity-drug developer Metsera and Novo Nordisk, seeking to block Metsera from terminating ...

Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer ...

Novo Nordisk has submitted an unsolicited bid to buy obesity biotech Metsera out from under Pfizer, offering $6 billion ...

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...

Novo Nordisk cuts over 800 jobs in Plainsboro, part of a global restructuring under the new CEO, reflecting a troubling trend ...

The chairman of Novo Nordisk and six other independent board members quit on Tuesday after a dispute with the company's ...

Pfizer has filed a lawsuit against Novo Nordisk and Metsera in an attempt to force through its takeover of the weight-loss drug developer and prevent Novo Nordisk from taking its rival bid forward.